Director’s Dealing

Verona Pharmaplc ("Verona Pharma" or the "Company") Director's Dealing 20 January 2015, Cardiff - Verona Pharma plc (AIM: VRP) yesterday receivednotification that on 19 January 2015 Mr Stuart Bottomley, Non-ExecutiveDirector of the Company, purchased via his SIPP 1,000,000 ordinary shares of0.1p each in the Company ("Ordinary Shares") at a price of 1.5 pence per share. Following the acquisition, Mr Bottomley will have an interest in the Company of20,000,000 Ordinary Shares, representing 1.98% of the Company's issued ordinaryshare capital. -Ends- For further information please contact: Verona Pharma plc Tel: +44 (0) 20 3283 4200 Jan-Anders Karlsson, CEO N+1 Singer Tel: +44 (0)20 7496 3000 Aubrey Powell / Jen Boorer FTI Consulting Tel: +44 (0)20 3727 1000 Julia Phillips / Simon Conway Notes to Editors About Verona Pharma plc Verona Pharma plc is a UK-based clinical stage biopharmaceutical companyfocused on the development of innovative prescription medicines to treatrespiratory diseases with significant unmet medical needs, such as COPD, asthmaand cystic fibrosis. Verona Pharma's lead drug, RPL554, is a first-in-classdrug currently in Phase II trials as a nebulised treatment for acuteexacerbations of COPD in the hospital setting. The drug is adual phosphodiesterase (PDE) 3/4 inhibitor and therefore has bothbronchodilator and anti-inflammatory effects, which are essential to theimprovement of patients with COPD and asthma. Verona Pharma is also building abroader franchise around RPL554 to maximise its value, both to patients and toinvestors. This includes the very significant markets for COPD and asthmamaintenance therapy. The Company is also exploring the potential of the drug indifferent diseases, such as cystic fibrosis, where it is in pre-clinicaltesting.